Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications

(2013) Vera Grossmann et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing

(2012) S.-Y. Ko et al.   CLINICAL MICROBIOLOGY AND INFECTION

Application of next-generation sequencing technologies in virology

(2012) A. D. Radford et al.   JOURNAL OF GENERAL VIROLOGY

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile

(2011) W. T. Parker et al.   BLOOD

Mutational analysis in chronic myeloid leukemia: when and what to do?

(2011) Susan Branford et al.   CURRENT OPINION IN HEMATOLOGY

Sensitive Detection ofBCR-ABL1Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy

(2011) Wendy T. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation

(2011) J. A. Schumacher et al.   JOURNAL OF CLINICAL PATHOLOGY

Detection of Minority Resistance during Early HIV-1 Infection: Natural Variation and Spurious Detection rather than Transmission and Evolution of Multiple Viral Variants

(2011) S. Gianella et al.   JOURNAL OF VIROLOGY

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories

(2011) A Kohlmann et al.   LEUKEMIA

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

(2010) F. X. Schaub et al.   BLOOD

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

(2010) Elias Jabbour et al.   CANCER

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

(2009) M. C. Muller et al.   BLOOD

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

(2009) E Jabbour et al.   LEUKEMIA

SeaView Version 4: A Multiplatform Graphical User Interface for Sequence Alignment and Phylogenetic Tree Building

(2009) M. Gouy et al.   MOLECULAR BIOLOGY AND EVOLUTION

Sequencing technologies — the next generation

(2009) Michael L. Metzker   NATURE REVIEWS GENETICS

Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid Leukemia

(2009) Elias Jabbour et al.   SEMINARS IN HEMATOLOGY

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

(2008) T. Ernst et al.   HAEMATOLOGICA

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia

(2008) J S Khorashad et al.   JOURNAL OF CLINICAL PATHOLOGY

High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain

(2008) Kateřina Machová Poláková et al.   LEUKEMIA RESEARCH

Next-generation DNA sequencing

(2008) Jay Shendure et al.   NATURE BIOTECHNOLOGY